Currently, there are 395.74M common shares owned by the public and among those 376.53M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -14.09% and 8.77% over the past three months. CLOV shares are trading 18.10% year to date (YTD), with the 12-month market performance up to 330.61% higher. It has a 12-month low price of $0.61 and touched a high of $4.87 over the same period. CLOV has an average intraday trading volume of 5.66 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.82%, -7.17%, and 28.23% respectively.
Institutional ownership of Clover Health Investments Corp (NASDAQ: CLOV) shares accounts for 18.57% of the company’s 395.74M shares outstanding.
It has a market capitalization of $1.86B and a beta (3y monthly) value of 2.02. The earnings-per-share (ttm) stands at -$0.09. The company has a debt-to-equity ratio at 0.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.01% over the week and 6.98% over the month.
Earnings per share for the fiscal year are expected to decrease by -80.25%, and 37.99% over the next financial year. EPS should grow at an annualized rate of 40.98% over the next five years, compared to -237.67% over the past 5-year period.
Looking at the support for the CLOV, a number of firms have released research notes about the stock. Craig Hallum stated their Buy rating for the stock in a research note on December 17, 2024, with the firm’s price target at $6. UBS coverage for the Clover Health Investments Corp (CLOV) stock in a research note released on October 07, 2024 offered a Neutral rating with a price target of $4. Cowen was of a view on February 02, 2022 that the stock is Market Perform, while Canaccord Genuity gave the stock Buy rating on February 02, 2022, issuing a price target of $6. SVB Leerink on their part issued Mkt Perform rating on January 19, 2022.
